Experimental murine L. major infection is characterized by the expansion of distinct CD4+ T cell subsets. The Th1 response is related to production of IFN-<FONT FACE="Symbol">g</font> and resolution of infection, whereas Th-2 response with production of IL-4 and IL-10 and dissemination of infection. The objective of this study was to measure the circulating levels of IFN-<FONT FACE="Symbol">g</font>, IL-10 and TNF-<FONT FACE="Symbol">a</font> in patients with visceral leishmaniasis (VL) before, during and at the end of therapy and to examine the association between cytokine levels and activity of VL. Fifteen patients with VL were evaluated. The cytokine determinations were done by using the enzyme-linked immunoassay (ELISA) before, during and at the end of therapy. At baseline, we detected circulating levels of IFN-<FONT FACE="Symbol">g</font> in 13 of 15 patients (median = 60 pg/ml); IL-10 in 14 of 15 patients (median = 141.4 pg/ml); and TNF-<FONT FACE="Symbol">a</font> in 13 of 14 patients (median = 38.9 pg/ml). As patients improved, following antimonial therapy, circulating levels of IL-10 showed an exponential decay (y = 82.34 e–0,10367x, r = –0.659; p < 0.001). IFN-<FONT FACE="Symbol">g</font> was no longer detected after 7/14 days of therapy. On the other hand, circulating levels of TNF-<FONT FACE="Symbol">a</font> had a less pronounced decay with time on therapy, remaining detectable in most patients during the first seven days of therapy (y = 36.99-0.933x, r = –0.31; p = 0.05). Part of the expression of a successful response to therapy may, therefore, include reduction in secretion of inflammatory as well as suppressive cytokines. Since IL-10 and IFN-<FONT FACE="Symbol">g</font> are both detected prior to therapy, the recognized cellular immune depression seen in these patients may be due to biological predominance of IL-10 (type 2 cytokine), rather than lack of IFN-<FONT FACE="Symbol">g </font>(type 1 cytokine) production.
Cytokines; IFN-<FONT FACE=Symbol>g </font>; IL-10; TNF-<FONT FACE=Symbol>a </font>; Visceral Leishmaniasis (Kala-Azar)
